Sleep Architecture, Cognitive Function, and Quality of Life During Early Recovery From Substance Use Disorder
Sleep Architecture, Cognitive Function, and Quality of Life During Early Recovery From Substance Use Disorder: A Controlled Prospective Cohort Study With Three-Month Follow-Up
This prospective cohort study investigates how sleep disturbances affect cognitive recovery and quality of life during early recovery from substance use disorder (SUD). Chronic substance use frequently alters normal sleep architecture, which may impair attention, memory, and everyday functioning. The primary aim is to characterize baseline sleep patterns in adults with SUD compared to healthy control participants and determine whether baseline sleep disruptions predict cognitive and functional recovery over three months of monitored abstinence.
The study includes two groups of participants aged 18 to 45 years: adults diagnosed with a primary substance use disorder undergoing treatment and monitored abstinence, and a comparison group of healthy volunteers matched for age, sex, education, work schedule, and caffeine or nicotine use.
At the beginning of the study, all participants complete:
- Structured diagnostic interviews and clinical assessments for mood, anxiety, and attention.
- Questionnaires evaluating subjective sleep quality (Pittsburgh Sleep Quality Index) and quality of life (WHOQOL-BREF).
- A global cognitive screening test (Montreal Cognitive Assessment) and a computerized attention test (Continuous Performance Task).
- An overnight sleep study (polysomnography) conducted in a sleep laboratory following an initial adaptation night to objectively record brain waves, sleep stages, oxygen levels, and sleep continuity.
Participants in the substance use disorder group undergo supervised abstinence monitoring via periodic clinical check-ins and random urine drug screens. At 1 month and 3 months post-baseline, participants repeat the cognitive tests, quality-of-life questionnaires, and mood/sleep assessments to track recovery trajectories over time (no repeat overnight sleep studies are performed).
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Adult patients aged 18 to 45 years diagnosed with a primary Substance Use Disorder according to DSM-5 criteria, admitted to inpatient wards or followed at outpatient clinics of the Neuropsychiatry Department at Assiut University Hospitals. A comparison group of age-, sex-, and education-matched adults without a substance use disorder is recruited from the local community, screened for the same psychiatric and sleep disorder exclusions, and matched on shift-work status as well as caffeine and nicotine consumption.
Descrição
Inclusion Criteria:
Substance Use Disorder (SUD) Cohort:
- Age between 18 and 45 years.
- Fulfillment of DSM-5 diagnostic criteria for a primary Substance Use Disorder.
- Admitted to inpatient wards or followed in outpatient neuropsychiatry services.
- Resolution of acute intoxication and clinically significant withdrawal prior to sleep assessment.
- Availability and willingness to complete baseline evaluations and prospective 1-month and 3-month follow-up assessments.
Matched Control Cohort:
- Age between 18 and 45 years.
- Absence of current or lifetime Substance Use Disorder.
- Matched to the SUD cohort by age, sex, education level, shift-work status, and caffeine/nicotine use.
- Availability and willingness to complete baseline and follow-up assessments.
Exclusion Criteria:
- Primary major independent psychiatric disorders predating the onset of substance use (e.g., schizophrenia, bipolar disorder).
- Pre-existing primary sleep disorders independent of substance use (e.g., previously diagnosed severe obstructive sleep apnea, narcolepsy).
- Current intake of prescription medications known to severely alter sleep architecture or cognitive function (e.g., chronic benzodiazepines, high-dose antipsychotics, antiepileptics).
- History of severe traumatic brain injury, neurological illness, or structural brain lesions.
- Acute psychiatric instability requiring urgent emergency clinical intervention.
- Impaired capacity to provide informed consent or conditions preventing valid completion of sleep studies or cognitive testing.
- Refusal to participate or withdrawal of consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Substance Use Disorder (SUD) Group
Adult patients aged 18 to 45 years fulfilling DSM-5 diagnostic criteria for a primary Substance Use Disorder recruited from the inpatient wards and outpatient clinics of the Neuropsychiatry Department at Assiut University Hospitals. Participants undergo monitored abstinence and receive baseline clinical evaluations, structured psychiatric assessment (SCID-5, PHQ-9, GAD-7, ASRS), subjective sleep quality assessment (PSQI), and overnight polysomnography (PSG). Follow-up prospective assessments of cognitive function (Continuous Performance Task, MoCA), quality of life (WHOQOL-BREF), and subjective sleep are completed at 1 month and 3 months. |
|
Matched Healthy Control Group
Adult volunteers aged 18 to 45 years without a Substance Use Disorder, matched to the SUD cohort by age, sex, education level, shift-work status, and caffeine/nicotine use. Participants are screened to rule out primary sleep, psychiatric, or neurological disorders and complete baseline clinical evaluations, psychiatric questionnaires, subjective sleep assessment (PSQI), and overnight polysomnography (PSG), followed by cognitive and quality of life assessments at 1 month and 3 months. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Continuous Performance Task (CPT) Reaction-Time Variability
Prazo: Baseline and 3 months
|
Assessed using a 14-minute computerized Continuous Performance Task (CPT) to evaluate sustained attention. It is calculated as the change in reaction-time standard deviation (in milliseconds) on correct target trials from baseline to the 3-month follow-up. A negative change score indicates improved stability of sustained attention. |
Baseline and 3 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Distúrbios Neurocognitivos
- Distúrbios Cognitivos
- Distúrbios induzidos quimicamente
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Disfunção cognitiva
- Transtornos Relacionados a Substâncias
- Distúrbios do Sono Vigília
Outros números de identificação do estudo
- Sleep in SUD Early Recovery
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .